Is the price fair?
What INBX's price assumes
Inhibrx Biosciences, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 886× revenue.
886
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 144
Price / book · as of 2025-Q4
- EV / sales
- 868
EV / sales
Details›
- Price / book2025-Q4
- 144
- EV / sales2025-Q4
- 868
- Market capitalisation
- $1.37B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.